Genomics AI firm Genomenon acquires Boston Genetics

By The Science Advisory Board staff writers

June 27, 2023 -- Genomenon on Tuesday said that it has acquired the genomics interpretation and curation firm Boston Genetics.

The expanded genomic interpretation team enabled by the acquisition supports its offerings for clinical diagnostic and pharmaceutical drug development programs, Genomenon said.

Financial and other terms of the deal were not disclosed.

Genomenon added that it is now in a position to curate the human genome by combining its artificial intelligence (AI)-enabled genomic platform and expertise with insights from Boston Genetics' team of genetic scientists.

The expanded team enables it to offer greater support to its clinical diagnostic and pharmaceutical clients by helping them better understand the genomic drivers of genetic disease and oncology, Genomenon said. The acquisition also creates a genomics data service arm for Genomenon that will enable genetic testing labs to speed up turnaround times, the firm said.

Effective immediately, the acquisition adds more than 75 trained genetic scientists, doubling the size of Genomenon. Boston Genetics' customers include U.S. genetic testing labs that will now have access to Genomenon's AI-enabled curation engine and services platform.

Boston Genetics has been a business partner with Genomenon for more than three years.

Bio-Techne to acquire Swiss spatial biology firm Lunaphore
Bio-Techne announced Thursday that it has reached an agreement to acquire Tolochenaz, Switzerland-based Lunaphore, a developer of fully automated spatial...
An unprecedented view of gene regulation
Massachusetts Institute of Technology (MIT) engineers have developed a technique to analyze the organization of the genome at a resolution 100 times higher...
New STING-seq approach pinpoints disease-causing genetic variants
Researchers are combining genome-wide association studies, CRISPR, and single-cell sequencing to discover causal variants and genetic mechanisms for blood...
After Illumina presentation highlighting Grail potential comes a possible EU fine
Illumina may be fined 10% of its annual revenues for completing the takeover of Grail in 2021 without European Union antitrust approval.
Cytiva acquires Cevec Pharmaceuticals to boost cell line development
Life sciences company Cytiva has acquired Cevec Pharmaceuticals for an undisclosed amount, which will further strengthen Cytiva's cell line development,...

Copyright © 2023

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter